Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease

Home
news
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease

Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease

Emulate signs a strategic partnership with the FDA

Prilenia shows positive effect on functional capacity in Huntigton's Disease

Recent Posts

Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board